# Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer

> **NCT01443377** · PHASE2 · COMPLETED · sponsor: **National Center for Tumor Diseases, Heidelberg** · enrollment: 48 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **BIOLOGICAL:** Panitumumab

## Key facts

- **NCT ID:** NCT01443377
- **Lead sponsor:** National Center for Tumor Diseases, Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-09
- **Final completion:** 2013-09
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2015-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01443377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01443377, "Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01443377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*